320 related articles for article (PubMed ID: 15695787)
1. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
[TBL] [Abstract][Full Text] [Related]
2. Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
Muzi M; Mankoff DA; Grierson JR; Wells JM; Vesselle H; Krohn KA
J Nucl Med; 2005 Feb; 46(2):371-80. PubMed ID: 15695799
[TBL] [Abstract][Full Text] [Related]
3. Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice.
Kim SJ; Lee JS; Im KC; Kim SY; Park SA; Lee SJ; Oh SJ; Lee DS; Moon DH
J Nucl Med; 2008 Dec; 49(12):2057-66. PubMed ID: 18997037
[TBL] [Abstract][Full Text] [Related]
4. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
5. Parametric Method Performance for Dynamic 3'-Deoxy-3'-
Kramer GM; Frings V; Heijtel D; Smit EF; Hoekstra OS; Boellaard R;
J Nucl Med; 2017 Jun; 58(6):920-925. PubMed ID: 28572289
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluorothymidine kinetics of malignant brain tumors.
Schiepers C; Chen W; Dahlbom M; Cloughesy T; Hoh CK; Huang SC
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1003-11. PubMed ID: 17295039
[TBL] [Abstract][Full Text] [Related]
8. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.
Frings V; Yaqub M; Hoyng LL; Golla SS; Windhorst AD; Schuit RC; Lammertsma AA; Hoekstra OS; Smit EF; Boellaard R;
J Nucl Med; 2014 Sep; 55(9):1417-23. PubMed ID: 24970910
[TBL] [Abstract][Full Text] [Related]
9. Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors.
Brockenbrough JS; Souquet T; Morihara JK; Stern JE; Hawes SE; Rasey JS; Leblond A; Wiens LW; Feng Q; Grierson J; Vesselle H
J Nucl Med; 2011 Aug; 52(8):1181-8. PubMed ID: 21764789
[TBL] [Abstract][Full Text] [Related]
10. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.
Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472
[TBL] [Abstract][Full Text] [Related]
11. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
[TBL] [Abstract][Full Text] [Related]
12. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
[TBL] [Abstract][Full Text] [Related]
13. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
[TBL] [Abstract][Full Text] [Related]
14. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
[TBL] [Abstract][Full Text] [Related]
15. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
[TBL] [Abstract][Full Text] [Related]
16. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
[TBL] [Abstract][Full Text] [Related]
17. Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer.
Visvikis D; Francis D; Mulligan R; Costa DC; Croasdale I; Luthra SK; Taylor I; Ell PJ
Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):169-78. PubMed ID: 15129698
[TBL] [Abstract][Full Text] [Related]
18. A simplified analysis of [18F]3'-deoxy-3'-fluorothymidine metabolism and retention.
Shields AF; Briston DA; Chandupatla S; Douglas KA; Lawhorn-Crews J; Collins JM; Mangner TJ; Heilbrun LK; Muzik O
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1269-75. PubMed ID: 15991018
[TBL] [Abstract][Full Text] [Related]
19. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies.
Vesselle H; Grierson J; Peterson LM; Muzi M; Mankoff DA; Krohn KA
J Nucl Med; 2003 Sep; 44(9):1482-8. PubMed ID: 12960196
[TBL] [Abstract][Full Text] [Related]
20. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
